NFKB1 and neoplasm: In our laboratory, we have already demonstrated that CFM-4.16 formulation in combination with sorafenib inhibited the growth of tumor xenografts formed from rociletinib-resistant H1975 NSCLC cells by inhibiting the NF-κB pathway [35] and TLM treatment significantly reduced the inflammatory and hyperproliferative changes in lung tissue after ovalbumin challenge in rats [81].